Clinical Trial Update: Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC [Phase 2]

View source ↗

Summary

This update describes a Phase 2 trial of Fruquintinib plus S-1 and Raltitrexed (RSF) for metastatic colorectal cancer, which is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• Raltitrexed (Raltitrexed)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Meng Qiu | Conditions: Fruquintinib, S-1 | Phase 2 | Status: RECRUITING